Effect of prior therapy on BRAF V600E-mutant metastatic colorectal cancer

Non-Sponsored Content

TARGETED THERAPY

Medical writer: Coco Chong | Last updated: 11 June 2021 | In: Gastrointestinal Cancer, Oncology, Targeted Therapies

Article Keywords

FOLFOXIRI, BRAF V600e-mutant, FOLFIRI, cetuximab, bevacizumab, oxaliplatin, encorafenib, mCRC

An exploratory post-hoc analysis of the BEACON CRC study investigated the overall survival (OS) of encorafenib + cetuximab (doublet) and FOLFIRI (control) according to prior therapies (bevacizumab, oxaliplatin, FOLFOXIRI and anticancer therapy [ACT]) in BRAF V600E-mutant metastatic colorectal cancer (mCRC).¹ Median OS (mOS) of the doublet therapy was 9.3 months and 5.9 months for control (HR 0.61; 95% CI: 0.5-0.8).¹

Patients who have received prior bevacizumab showed mOS of 8.3 months (95% CI: 6.2-11.2) and 5.1 months (95% CI: 4.0-6.4) in the doublet and control arms respectively (HR 0.53, 95% CI: 0.4-0.7).¹ Of those who received less than 4 months of prior treatment, mOS of 10.7 months (95% CI: 7.5-17.7) and 4.4 months (95% CI: 2.0-11.6) were reported (HR 0.47; 95% CI: 0.2-1.0).¹ In those who received ≥4 months of prior treatment, mOS was 9.4 months (95% CI: 7.6-16.5) and 7.4 months (95% CI: 5.6–9.5) (HR 0.71; 95% CI: 0.5-1.1).¹

For patients who have received prior oxaliplatin treatment, mOS of 9.7 months and 6.4 months (HR 0.6; 95% CI: 0.4–0.8) were reported in doublet and control groups, compared to patients who didn’t receive prior oxaliplatin with 8.4 months (95% CI: 3.6–NR) and 6.5 months (95% CI: 3.2–NR) (HR 0.73; 95% CI: 0.2-2.7), respectively.¹

Patients who were on FOLFOXIRI treatments demonstrated a mOS of 9.4 months (95% CI: 5.3-17.7) and 4.6 months (95% CI: 2.1-NR) (HR 0.63; 95% CI: 0.3–1.3), while those without had a mOS of 10.7 months (95% CI: 8.3-12.6) and 6.5 months (95% CI: 5.6-8.8) (HR 0.59; 95% CI: 0.4-0.8).¹

In prior ACT treatments, a duration of less than or equal to 6 months reported an 8.8 month of mOS (95% CI: 7.6–10.7) on the doublet arm and 5.8 months (95% CI: 4.8–7.3) on the controlled arm.¹ An increased mOS of 11.3 months (95% CI: 8.4-17.7) and 6.5 months (95% CI: 4.8-11.3) was observed for more than 6 months of prior ACT treatment (HR 0.61; 95% CI: 0.4-0.9).¹

Reference

Kopetz S, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 3583)

At the Heart of the Discussion: COVID-19 Cardiovascular Complications in Pregnant Women

Vaccination versus Active Infection: A Comparison of the Cardiovascular Risks

Common Respiratory Viruses and Their Associated Cardiovascular Risks

Personalised Angina Treatment at Cellular Level

Previous Next

At the Heart of the Discussion: COVID-19 Cardiovascular Complications in the Pregnant Women

6 November 2022

At the Heart of the Discussion: COVID-19 Cardiovascular Complications in Pregnant Women

26 August 2022

Vaccination versus Active Infection: A Comparison of the Cardiovascular Risks

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).